Supplementary Table 1 Demographic and clinical information at baseline in patients with and without follow-up data

Items	Patients with		Patients without	Sig.
	follow-up	data	follow-up data	
	(n=119)		(n=87)	
Age (years)	22 (9)		24 (12)	0.004
Educational years	14.33±2.66		14.77 ± 2.40	0.218
BMI (kg/m^2)	22.43 ± 4.78		21.45±3.60	0.108
Gender (Female), No. (%)	87 (73.1)		61 (70.1)	0.637
Marriage (Unmarried), No. (%)	94 (79.0)		62 (71.3)	0.326
Ethnic (Han), No. (%)	109 (91.6)		78 (89.7)	0.634
History of drinking, No. (%)	22 (18.5)		19 (21.8)	0.072
History of smoking, No. (%)	17 (14.3)		15 (17.2)	0.663
Depressive episodes	2(1)		1(1)	0.185
HAMD-17 score	21.94±5.05		20.77 ± 5.88	0.295
HAMA score	21.51±7.58		21.20±7.52	0.426
BSSI score	7.57 ± 7.52		8.76 ± 7.86	0.129
SDS score	19.01±6.07		17.82 ± 5.76	0.098
PDQ-5 score	11.69±3.46		12.15±3.64	0.349
Antidepressants				
SSRIs, No. (%)	43 (36.1)		23 (26.4)	0.141
SNRIs, No. (%)	12 (10.1)		8 (9.2)	0.832
SARIs, No. (%)	62 (52.1)		36 (41.4)	0.128
Others ^a , No. (%)	7 (5.9)		7 (8.0)	0.542
Neuroticism score	44.92±5.97		44.89 ± 6.64	0.950
T-AI score	59.98±7.06		59.73±7.43	0.824
PSS score	24.76±4.96		24.66±4.53	0.820
S-AI score	56.64±8.67		56.88 ± 9.48	0.895

Note: Significance (P < 0.05) indicated in bold. BMI, Body Mass Index. HAMD-17, 17-item Hamilton Depression Scale. HAMA, Hamilton Anxiety Scale. BSSI, Beck Scale for Suicide Ideation. SDS, Sheehan Disability Scale. PDQ-5, Perceived Deficits Questionnaire five-item version. SSRIs, Selective Serotonin Reuptake Inhibitors. SNRIs, Serotonin-Norepinephrine Reuptake Inhibitors. SARIs, Serotonin Receptor Antagonists and Reuptake Inhibitors. T-AI, Trait Anxiety Inventory of State-Trait Anxiety Inventory. PSS, Perceived Stress Scale. S-AI, State Anxiety Inventory of State-Trait Anxiety Inventory. a Others include Noradrenergic and Specific Serotonergic Antidepressants and Norepinephrine-Dopamine Reuptake Inhibitors.

Supplementary Table 2 Comparison of proportion of stress-sensitivity factors between patients with and without clinical remission at the end of follow-up

Items	Patients with clinical remission (n=44)	Patients without clinical remission (n=75)	Z/F	Sig.
Proportion of all high-level factors, No. (%)	2 (4.5%)	8 (10.7%)	7.747	0.096
Proportion of high-level trait-related factors, No. (%)	2 (4.5%)	18 (24.0%)	7.542	0.023
Proportion of high-level state-related factors, No. (%)	6 (13.6%)	10 (13.3%)	1.503	0.472

Note: Significance (P < 0.05) indicated in bold. Stress-sensitivity factors include neuroticism, trait anxiety, perceived stress, and state anxiety, with trait-related factors including neuroticism and trait anxiety and state-related factors including perceived stress and state anxiety. Patients with high-level neuroticism were defined by the highest quartile (Neuroticism score ≥ 48 , ranging 48–59). Patients with high-level state anxiety and trait anxiety were defined by S-AI ≥ 62 (ranging 62–78) and T-AI ≥ 65 (ranging 65–78) based on the average of the 75th percentile score. Patients with high-level perceived stress were defined by PSS ≥ 28 (ranging 28–36) based on the average of the 75th percentile score.